Jubilant Pharmova Limited — Investor Meet, 16-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Pharmova has announced a board meeting to consider the financial results for the quarter and half-year. The management is engaging institutional investors in Mumbai through one-on-one and group sessions during a Specialty Chemicals and Healthcare Investor Conference. The company’s diverse revenue streams include Radiopharma, CDMO Sterile Injectables, CRDMO, Allergy Immunotherapy, and Generics, with 80% from the US. Focus areas include capacity expansion in sterile injectables, new radiopharma launches, allergy immunotherapy scale-up, CDMO growth, and advancing novel drug trials. Targets include doubling revenue and achieving 23-25% EBITDA margins with zero net debt by FY30.